GlassScriptPhysician profile
Kathy K Oconnell
NPI 1114939980
$1,579.23
in general payments reported to CMS, 2019-2025
22 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.95 · 2020: $35.74 · 2021: $7.61 · 2022: $409 · 2023: $422 · 2024: $494 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945 · Education: $86.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.04 |
| Education | $86.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $205.40 | 2023-2024 | Veozah, Myrbetriq |
| Organon LLC | $189.28 | 2021-2024 | Nexplanon |
| Shield Therapeutics INC | $173.35 | 2023-2025 | Accrufer |
| Daiichi Sankyo INC. | $158.67 | 2024-2025 | Injectafer |
| Sumitomo Pharma America, INC. | $117.03 | 2023-2024 | Myfembree |
| Abbvie INC. | $116.01 | 2019-2024 | |
| Myovant Sciences INC. | $100.18 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.91 | 2022-2023 | |
| Exeltis, USA INC. | $73.65 | 2022-2024 | Slynd |
| Pfizer INC. | $59.44 | 2024 | |
| Merck Sharp & Dohme LLC | $47.81 | 2019-2020 | |
| Karl Storz Endoscopy-America | $43.38 | 2022 | |
| Therapeuticsmd, INC. | $31.41 | 2019-2020 | |
| Mycovia Pharmaceuticals, INC. | $28.41 | 2022-2023 | Vivjoa |
| Mayne Pharma Commercial LLC | $26.41 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $25.95 | 2022 | |
| Meditrina | $25.41 | 2023-2024 | |
| Biogen, INC. | $22.75 | 2025 | Zurzuvae |
| Alexion Pharmaceuticals, INC. | $21.88 | 2024 | Ultomiris |
| Covidien LP | $14.91 | 2019 | |
| Minerva Surgical, INC | $13.99 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Oconnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.